Local–regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study
Cancer Immunology, Immunotherapy · 15.07.2025 · 74 (8)
DOI: 10.1007/s00262-025-04129-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 15.07.2025. Verfasst von Shuofeng Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Chin…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Phenylurea Compounds, Quinolines, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Research Funding of PUMCH.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Chemotherapy combined with immune checkpoint inhibitors (ICIs) remains the first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC) but is limited by suboptimal efficacy. While local-regional therapy plus ICIs and lenvatinib (triple therapy) has demonstrated antitumor activity in biliary tract cancers, its role in ICC remains unclear. This multicenter study compared the effectiveness and tolerability of this triple therapy versus chemotherapy plus ICIs in advanced ICC. METHODS: Advanced ICC patients receiving first-line local-regional therapy (radiotherapy, hepatic arterial infusion chemotherapy, or transarterial chemoembolization) plus ICIs and lenvatinib or chemotherapy plus ICIs were screened. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), adverse events (AEs). RESULTS: A total of 78 patients receiving triple therapy and 70 patients receiving chemotherapy plus ICIs were included. The triple therapy group exhibited significantly prolonged median PFS (10.8 vs. 7.6 months, P = 0.011) and median OS (18.5 vs. 15.0 months, P = 0.040), along with higher ORR (51.3% vs. 27.1%) and DCR (85.9% vs. 81.4%). Grade 3-4 AEs occurred more frequently in the triple therapy group (60.3% vs. 58.6%), this difference lacked statistical significance (P = 0.968). No grade 5 events were reported, and all AEs were manageable. Multivariate analysis identified CEA as an independent prognostic factor for PFS and OS. CONCLUSION: Local-regional therapy plus ICIs and lenvatinib demonstrated superior efficacy and manageable toxicity, establishing it as a viable first-line regimen for advanced ICC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, China.
- Department of Hepatobiliary and Pancreatic Surgery, China-Japan Friendship Hospital, Beijing, China. sunyongliang1982@hotmail.com.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. wenwen0605@163.com.
- Department of Hepatobiliary Surgery, The Fifth Medical Center of PLA General Hospital, Beijing, China. zhuzy302@163.com.
Förderung
- National High Level Hospital Clinical Research Funding of PUMCH
Zitieren
APA
Li, S., Yu, G., Wang, M., Feng, S., Zhang, A., Wu, Y., Zhou, Z., Wang, S., Zhang, Y., Piao, M., Li, C., Xun, Z., Sun, B., Li, J., Zhang, N., Li, H., Sun, Y., Zhang, W., Zhu, Z., & Zhao, H. (2025). Local–regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study. Cancer Immunology, Immunotherapy, 74(8). https://doi.org/10.1007/s00262-025-04129-6
Vancouver
Li S, Yu G, Wang M, Feng S, Zhang A, Wu Y, et al. Local–regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study. Cancer Immunology, Immunotherapy. 2025;74(8). doi:10.1007/s00262-025-04129-6
BibTeX
@article{Li2025,
author = {Li, Shuofeng and Yu, Guanhua and Wang, Mingming and Feng, Shi and Zhang, An and Wu, Yu and Zhou, Zixiang and Wang, Shanshan and Zhang, Yihong and Piao, Mingjian and Li, Chengjie and Xun, Ziyu and Sun, Boyu and Li, Jiongyuan and Zhang, Nan and Li, Hu and Sun, Yongliang and Zhang, Wen and Zhu, Zhenyu and Zhao, Haitao},
title = {Local–regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {8},
doi = {10.1007/s00262-025-04129-6}
}
EUVIMED